Rubidomycin pp 155-163 | Cite as

Treatment of Chronic Leukemia, Sarcoma, Hodgkin’s Disease, and Cancer with Rubidomycin

  • J. Bernard
  • R. Paul
  • M. Boiron
  • Cl. Jacquillat
  • R. Maral
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 20)

Abstract

Chronic myelocytic period. Many therapeutic agents, among which Busulfan and radiotherapy occupy the first rank but which also include 6-mercaptopurine, dibromomannitol, and hydroxyurea, can bring about good remissions in chronic myeloid leukemia. There are thus two important questions to answer in relation to the use of rubidomycin as a therapeutic agent: 1. can it bring about remission in this condition? and 2. what advantages does it have over the drugs already known? It is easy at present to answer the first of these questions, for rubidomycin is indeed very effective. It is difficult to answer the second.

Keywords

Leukemia Sarcoma Streptomyces Myeloma Mannitol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin · Heidelberg 1969

Authors and Affiliations

  • J. Bernard
  • R. Paul
  • M. Boiron
  • Cl. Jacquillat
  • R. Maral

There are no affiliations available

Personalised recommendations